Business Review Document 2009
Download
PDF (1.7Mb)
News
News
18.03.2010
Elan Drug Technologies Announces Pivotal Phase 3 Trial for Hydrocodone Controlled Release Fomulation by its Licensing Partner Zogenix Inc
01.03.2010
Elan Drug Technologies Welcomes the Launch of MS Drug AMPYRA™ (Dalfampridine) Extended Release Tablets
25.01.2010
Elan Drug Technologies Welcomes the NDA Approval of MS Drug AMPYRA™ (Dalfampridine) Extended Release Tablets
View all News
RSS
Events
Events
October 5-7
CPhI Worldwide Annual Meeting
Paris Nord Villepinte, France
November 14-18
AAPS Annual Meeting and Exposition / FIP2010 World Congress
New Orleans, Louisiana, USA
November 15-17
BioEurope 2010
Munich, Germany
View all Events
RSS
Features & Publications
Elan Drug Technologies wins technology innovation award at 14th Annual Drug Delivery Partneship Meeting
Download PDF (1.14Mb)
View all Features and Publications
Case Studies
Improve patient compliance and convenience with NanoCrystal® technology
Read Rapamune® case study
Enhance patient acceptability - create a branded opportunity
Read Megace® ES case study
Night-time dosed therapy minimising risk of early morning cardiovascular events
Read Verelan® PM case study
Round the clock analgesia with once daily, novel dual release, oral morphine therapy
Read Avinza® case study
© 2009, Elan Drug Technologies, Monksland, Athlone, Co Westmeath, Ireland
Tel: +353 9064 95000 | Email: edtqueries@elan.com | Trademarks | Privacy policy | Terms of Use | 
Elan Corporation, plc. Registered Office: Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland. Registered in Ireland, Number 30356.